Cargando…
TOCILIZUMAB USE IN SEVERE COVID-19: A SINGLE CENTER EXPERIENCE
Autores principales: | Poon, Joseph, Ho, Kam Sing, Herrera, Yasmin, Jean, Raymonde |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American College of Chest Physicians. Published by Elsevier Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7548671/ http://dx.doi.org/10.1016/j.chest.2020.08.646 |
Ejemplares similares
-
CLINICAL OUTCOMES IN DIABETIC VS NON-DIABETIC PATIENTS WITH SEVERE COVID-19
por: Poon, Joseph, et al.
Publicado: (2020) -
SEIZURES AS THE INITIAL PRESENTATION OF COVID-19: A NOVEL CASE OF SYNDROME OF INAPPROPRIATE ANTIDIURETIC HORMONE
por: Ho, Kam Sing, et al.
Publicado: (2020) -
TOCILIZUMAB IN COVID-19: EAST-AFRICAN EXPERIENCE
por: SHAH, R., et al.
Publicado: (2022) -
PNEUMOTHORAX IN SEVERELY ILL PATIENTS WITH COVID-19: SINGLE-CENTER RETROSPECTIVE CASE SERIES
por: SHAH, ROSHAN, et al.
Publicado: (2021) -
IMPROVED SURVIVAL OUTCOME IN PATIENTS WITH SARS-COV-2 (COVID-19) ARDS WITH TOCILIZUMAB ADMINISTRATION
por: Wadud, Nafisa, et al.
Publicado: (2020)